Tomegavax, Inc.

Part of VIR Biotechnology, Inc.

UEI
NUE6Q16X2GL1
CAGE
6EXF1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A cytomegalovirus-based therapeutic vaccine for chronic hepatitis B R44AI129232 National Institute of Allergy and Infectious Diseases (NIH) $1,982,523
A cytomegalovirus vectored chagas disease therapeutic vaccine R43AI126963 National Institute of Allergy and Infectious Diseases (NIH) $224,959
An effector memory T cell-based therapeutic cervical cancer vaccine R43CA180177 National Institutes of Health $224,671
A cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses R44CA180177 National Cancer Institute (NIH) $1,876,513
CMV vectored herpes simplex vaccine R41AI109927 National Institutes of Health $299,863

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Tomegavax, Inc. registered in SAM.gov?

Tomegavax, Inc.'s SAM.gov registration expired on January 31, 2022.

What is Tomegavax, Inc.'s CAGE code?

Tomegavax, Inc.'s CAGE code is 6EXF1, and its Unique Entity ID (UEI) is NUE6Q16X2GL1.

What is Tomegavax, Inc.'s most recent federal award?

Tomegavax, Inc.'s most recent federal grant award is A cytomegalovirus-based therapeutic vaccine for chronic hepatitis B (R44AI129232), from National Institute of Allergy and Infectious Diseases (NIH), on March 3, 2017.

On GovTribe

See Tomegavax, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe